Mirna Therapeutics, an Austin, TX-based clinical-stage biopharmaceutical and immuno-oncology company focused on the development of microRNA-based cancer therapeutics, completed a $41.8m Series D financing.
The round was led by Baxter Ventures, with participation from new investors Eastern Capital, Santé Ventures, Morningside Ventures, Rock Springs Capital, and Celgene Corporation and existing investors Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners, Correlation Ventures, and others.
The company intends to use the funds to advance its lead microRNA (miRNA) therapeutic product candidate, MRX34, into Phase 1b and Phase 2 trials in 2016, and a second miRNA therapeutic candidate into clinical trials, as well as embark on a combination therapy development program.
Led by Paul Lammers, M.D., President and Chief Executive Officer, Mirna develops a broad pipeline of microRNA-based oncology therapeutics. Its lead program, MRX34, is a miRNA mimic drug candidate to advance into clinical testing. It is currently being studied in a Phase 1 clinical trial including patients with hepatocellular carcinoma, other solid tumors and hematological malignancies.